康拓医疗(688314) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥86,777,991.20, representing a year-on-year increase of 21.41%[2] - Net profit attributable to shareholders was ¥27,921,006.76, reflecting a growth of 10.95% compared to the same period last year[2] - Basic earnings per share (EPS) for the quarter was ¥0.34, a rise of 9.68% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached ¥240,117,907.83, an increase of 16.2% compared to ¥206,601,313.31 in the same period of 2023[18] - Operating profit for the first three quarters of 2024 was ¥91,974,599.66, up from ¥76,816,522.05 in 2023, reflecting a growth of 19.3%[18] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was ¥76,713,229.82, compared to ¥64,346,824.69 in 2023, marking an increase of 19.5%[19] - The company reported a total profit of ¥92,332,439.71 for the first three quarters of 2024, compared to ¥77,054,382.41 in 2023, an increase of 19.7%[19] - The company recorded a net profit margin of approximately 31.6% for the first three quarters of 2024, compared to 30.8% in the same period of 2023[19] Cash Flow and Investments - The net cash flow from operating activities amounted to ¥33,736,059.15, with a significant increase of 69.37% year-to-date[8] - In the first three quarters of 2024, the company generated operating cash inflow of CNY 288,963,805.42, an increase of 14.9% compared to CNY 251,458,415.59 in the same period of 2023[21] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 109,654,732.43, up from CNY 64,742,464.57 in 2023, representing a significant increase of 69.2%[22] - The company reported a total cash outflow from investing activities of CNY 498,816,423.88 in 2024, a decrease from CNY 700,533,529.94 in 2023, indicating a reduction of 28.8%[22] - The company incurred a net cash outflow from financing activities of CNY 29,942,653.10 in Q3 2024, slightly improved from CNY 30,628,196.86 in Q3 2023[22] - The cash inflow from investment activities in Q3 2024 was CNY 347,020,186.10, down from CNY 551,616,423.99 in Q3 2023, a decrease of 37.0%[22] - The company reported a cash outflow of CNY 420,000,000.00 related to investment activities in Q3 2024, down from CNY 674,500,000.00 in Q3 2023, indicating a decrease of 37.7%[22] Research and Development - Research and development (R&D) expenses totaled ¥8,183,154.79 for the quarter, marking a 49.90% increase, attributed to projects entering clinical trial phases[8] - The proportion of R&D expenses to operating revenue was 9.43%, an increase of 1.79 percentage points compared to the same period last year[4] - Research and development expenses for the first three quarters of 2024 amounted to ¥16,399,769.03, up from ¥13,734,653.11 in 2023, indicating a growth of 19.4%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥737,663,275.58, up 9.16% from the end of the previous year[4] - The company's total current assets as of September 30, 2024, amount to RMB 417,813,421.07, a decrease from RMB 426,650,740.33 at the end of 2023[14] - The total non-current assets increased to RMB 319,849,854.51 from RMB 249,136,662.79 in the previous year[15] - The total liabilities increased to ¥96,906,684.48 in Q3 2024 from ¥90,277,053.85 in Q3 2023, representing an increase of 7.1%[18] - Accounts payable increased to RMB 26,968,968.48 from RMB 16,844,707.96, indicating a rise of approximately 60.5%[15] Shareholder Information - Shareholders' equity attributable to the parent company reached ¥638,401,914.54, reflecting an 8.72% increase from the previous year[4] - The total equity attributable to shareholders of the parent company increased to ¥638,401,914.54 in Q3 2024 from ¥587,184,063.37 in Q3 2023, a rise of 8.7%[18] - The total number of common shareholders at the end of the reporting period is 81,200, with the top 10 shareholders holding 77.67% of the shares[10] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of the total shares[10] Employee Compensation - The company paid CNY 58,452,631.10 in employee compensation in the first three quarters of 2024, an increase of 13.5% from CNY 51,616,821.83 in the same period of 2023[21]